Guidelines for the clinical evaluation of lipid-altering agents in adults and children.

Saved in:
Bibliographic Details
Language:English
Format: Book E-Resource
id ocm07742025
ctrlnum (OCoLC)7742025
institution The University of Chicago
collection Hathi Collection
building Internet
fullrecord 01738cam a2200457 a 4500001001300000007000300013003000600016005001700022008004100039040002300080016001800103019001200121029001700133035003500150037002500185050001500210060002100225074001000246086002200256049000900278245009200287246004900379260018700428300001500615490004400630500009300674500001700767500004000784650003500824650002100859650004100880650001900921650002000940650002700960650002600987710010401013710006801117830004501185830003801230994001201268ocm07742025 crOCoLC20100309033852.0810620s1980 mdu o000 0 eng  aNLMcNLMdGPOdVNN7 a81046692DNLM a73211640 aNLMb8104669 a(OCoLC)7742025z(OCoLC)7321164 a017-012-00288-9bGPO 4aRM300b.U600aQU 85bG946 1980 a499-K0 aHE 20.4208/2:L 66 aCGUA00aGuidelines for the clinical evaluation of lipid-altering agents in adults and children.3 aLipid-altering agents in adults and children aRockville, Md. :bDivision of Metabolism and Endocrine Drug Products, Bureau of Drugs, Food and Drug Administration ; Washington : For sale by the Supt. of Docs., U.S. G.P.O.,c1980. aiii, 10 p.1 aFDA Bureau of Drugs clinical guidelines aDeveloped by the FDA Bureau of Drugs with the assistance of various advisory committees. a"July 1980." aHHS publication ; no (FDA) 80-3103. 2aAntilipemic Agentsxstandards. 2aDrug Evaluation. 2aHyperlipoproteinemiasxdrug therapy. 2aLipidsxblood. 0aDrugsxTesting. 0aBlood lipidsxTesting. 0aHyperlipoproteinemia.1 aUnited States.bFood and Drug Administration.b Division of Metabolism and Endocrine Drug Products.1 aUnited States.bFood and Drug Administration.bBureau of Drugs. 0aFDA Bureau of Drugs clinical guidelines. 0aHHS publication ;v(FDA) 80-3103. aC0bCGU
record_format hathi
spelling Guidelines for the clinical evaluation of lipid-altering agents in adults and children.
Lipid-altering agents in adults and children
Rockville, Md. : Division of Metabolism and Endocrine Drug Products, Bureau of Drugs, Food and Drug Administration ; Washington : For sale by the Supt. of Docs., U.S. G.P.O., 1980.
iii, 10 p.
FDA Bureau of Drugs clinical guidelines
Developed by the FDA Bureau of Drugs with the assistance of various advisory committees.
"July 1980."
HHS publication ; no (FDA) 80-3103.
Antilipemic Agents standards.
Drug Evaluation.
Hyperlipoproteinemias drug therapy.
Lipids blood.
Drugs Testing.
Blood lipids Testing.
Hyperlipoproteinemia.
United States. Food and Drug Administration. Division of Metabolism and Endocrine Drug Products.
United States. Food and Drug Administration. Bureau of Drugs.
FDA Bureau of Drugs clinical guidelines.
HHS publication ; (FDA) 80-3103.
language English
format Book
E-Resource
author2 United States. Food and Drug Administration. Division of Metabolism and Endocrine Drug Products
United States. Food and Drug Administration. Bureau of Drugs
author_facet United States. Food and Drug Administration. Division of Metabolism and Endocrine Drug Products
United States. Food and Drug Administration. Bureau of Drugs
United States.Food and Drug Administration. Division of Metabolism and Endocrine Drug Products
United States.Food and Drug Administration.Bureau of Drugs
title Guidelines for the clinical evaluation of lipid-altering agents in adults and children.
spellingShingle Guidelines for the clinical evaluation of lipid-altering agents in adults and children.
FDA Bureau of Drugs clinical guidelines
FDA Bureau of Drugs clinical guidelines.
HHS publication ;
Developed by the FDA Bureau of Drugs with the assistance of various advisory committees.
"July 1980."
HHS publication ; no (FDA) 80-3103.
Antilipemic Agents standards.
Drug Evaluation.
Hyperlipoproteinemias drug therapy.
Lipids blood.
Drugs Testing.
Blood lipids Testing.
Hyperlipoproteinemia.
title_short Guidelines for the clinical evaluation of lipid-altering agents in adults and children.
title_short_exact Guidelines for the clinical evaluation of lipid-altering agents in adults and children.
title_full Guidelines for the clinical evaluation of lipid-altering agents in adults and children.
title_fullStr Guidelines for the clinical evaluation of lipid-altering agents in adults and children.
title_full_unstemmed Guidelines for the clinical evaluation of lipid-altering agents in adults and children.
title_full_exact Guidelines for the clinical evaluation of lipid-altering agents in adults and children.
title_author Guidelines for the clinical evaluation of lipid-altering agents in adults and children.
title_author_exact Guidelines for the clinical evaluation of lipid-altering agents in adults and children.
title_alt Lipid-altering agents in adults and children
title_alt_exact Lipid-altering agents in adults and children
title_sort guidelines for the clinical evaluation of lipid altering agents in adults and children
title_browse Guidelines for the clinical evaluation of lipid-altering agents in adults and children.
Lipid-altering agents in adults and children
title_browse_sort Guidelines for the clinical evaluation of lipid-altering agents in adults and children
Lipid-altering agents in adults and children
series FDA Bureau of Drugs clinical guidelines
FDA Bureau of Drugs clinical guidelines.
HHS publication ;
series2 FDA Bureau of Drugs clinical guidelines.
HHS publication ; (FDA) 80-3103.
series_browse FDA Bureau of Drugs clinical guidelines
HHS publication
series_facet FDA Bureau of Drugs clinical guidelines
HHS publication
publisher Division of Metabolism and Endocrine Drug Products, Bureau of Drugs, Food and Drug Administration ; Washington : For sale by the Supt. of Docs., U.S. G.P.O.,
publishDate 1980
publication_place Rockville, Md. :
physical iii, 10 p.
contents Developed by the FDA Bureau of Drugs with the assistance of various advisory committees.
"July 1980."
HHS publication ; no (FDA) 80-3103.
topic Antilipemic Agents standards.
Drug Evaluation.
Hyperlipoproteinemias drug therapy.
Lipids blood.
Drugs Testing.
Blood lipids Testing.
Hyperlipoproteinemia.
topic_facet Antilipemic Agents
Drug Evaluation
Hyperlipoproteinemias
Lipids
Drugs
Blood lipids
Hyperlipoproteinemia
standards
drug therapy
blood
Testing
notes Developed by the FDA Bureau of Drugs with the assistance of various advisory committees.
"July 1980."
HHS publication ; no (FDA) 80-3103.
illustrated Not Illustrated
oclc_num 7742025
_version_ 1735318025987424256
import_time 2022-06-11T06:17:11.912Z